Editorial
Research studies
Editorial summaries of selected peptide research literature, written for a technically literate audience. Each note cites the underlying published studies.
Prefer the big picture? Read the monthly research roundup — what the literature showed, what changed, and what's new in the library.
- 2026.09.15Healing
BPC-157: the body-protection compound and its exceptionally broad healing record
Why BPC-157 has become the most discussed healing peptide in the field: a 25-year preclinical record, a clear angiogenic mechanism, and consistent tendon, ligament, and gut findings.
Read full note - 2026.09.12Metabolic
Ultratrutide: the newest incretin — triple-agonist power built around muscle preservation
A look at one of the newest compounds in the incretin class, designed on the retatrutide template with lean-mass protection as the headline goal — and why the triple-agonist mechanism makes that plausible.
Read full note - 2026.09.10Cognitive
Semax and Selank: brain-first peptides with real clinical histories
Two registered intranasal nootropic peptides — an ACTH-derived BDNF modulator and a tuftsin-derived anxiolytic — and why the research points to complementary cognitive and stress benefits.
Read full note - 2026.09.08Performance
CJC-1295 and ipamorelin: restoring the growth-hormone axis with two complementary secretagogues
A long-acting GHRH analog with published human data and the most selective ghrelin-mimetic secretagogue — the pharmacology behind the most popular pairing in GH-axis research.
Read full note - 2026.06.10Metabolic
Long-term cardiovascular outcomes with GLP-1 agonism: a reading of SELECT follow-up data
A summary of secondary endpoints reported in the SELECT cardiovascular outcomes trial, with attention to methodological caveats around dropout and unblinding.
Read full note - 2026.05.28Metabolic
Tirzepatide and Retatrutide: a new generation of multi-receptor incretins
A review of the published Phase 3 evidence for tirzepatide (SURPASS, SURMOUNT) and the Phase 2 results for retatrutide, highlighting the magnitude of weight loss, glycemic control, and emerging cardiometabolic benefits reported in peer-reviewed trials.
Read full note - 2026.04.30Longevity
Mitochondrial-derived peptides: signal or noise?
Mapping the MOTS-c, humanin, and SHLP literature against current standards for in vivo metabolic and longevity claims.
Read full note - 2026.04.15Editorial
Reading the dose-response curve: a primer on receptor-saturation thinking
A short methodology note explaining why peak-effect plateaus complicate naive linear-dose comparisons across studies.
Read full note